These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8467859)

  • 1. Antidiuretic activity and release of factor VIII by vasopressin analogues.
    Vilhardt H; Barth T; Melin P; Aurell CJ
    Eur J Pharmacol; 1993 Mar; 232(2-3):223-6. PubMed ID: 8467859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and some pharmacological properties of deamino(4-threonine,8-D-arginine)vasopressin and deamino(8-D-arginine)vasopressin, highly potent and specific antidiuretic peptides, and (8-D-arginine)vasopressin and deamino-arginine-vasopressin.
    Manning M; Balaspiri L; Moehring J; Haldar J; Sawyer WH
    J Med Chem; 1976 Jun; 19(6):842-5. PubMed ID: 950656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The release of factor VIII and tissue plasminogen activator can not be blocked by specific antagonists to vasopressin.
    Vilhardt H; Barth T
    J Recept Res; 1991; 11(1-4):239-45. PubMed ID: 1909360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelial stimulation by DDAVP in von Willebrand's disease and haemophilia.
    Greer IA; McLaren M; Belch JJ; Lowe GD; Forbes CD
    Haemostasis; 1986; 16(1):15-9. PubMed ID: 3084364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [DDAVP: alternative to replacement treatment in mild haemophilia A and von Willebrand-Jürgens syndrome (author's transl)].
    Theiss W; Sauer E
    Dtsch Med Wochenschr; 1977 Dec; 102(48):1769-72. PubMed ID: 303563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the disulfide bridge and the C-terminal tripeptide in the antidiuretic action of vasopressin in man and the rat.
    Cort JH; Schück O; Stríbrná J; Skopková J; Jost K; Mulder JL
    Kidney Int; 1975 Nov; 8(5):292-302. PubMed ID: 1195561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of desamino-D-arginine vasopressin (DDAVP) and naloxone infusions on factor VIII and possible endothelial cell (EC) related activities.
    Moffat EH; Giddings JC; Bloom AL
    Br J Haematol; 1984 Aug; 57(4):651-62. PubMed ID: 6430337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DDAVP-induced changes of factor VIII-related activities and bleeding time in patients with von Willebrand's syndrome.
    Schmitz-Huebner U; Balleisen L; Arends P; Pollmann H; Sutor AH
    Haemostasis; 1980; 9(4):204-13. PubMed ID: 6772527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specificity in the factor VIII response to vasopressin infusion in man.
    Prowse CV; Sas G; Gader AM; Cort JH; Cash JD
    Br J Haematol; 1979 Mar; 41(3):437-47. PubMed ID: 427046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of neurohypophyseal hormone analogues on blood clotting factor VIII and fibrinolytic activity in sheep.
    Neuenschwander S; Pliska V
    Eur J Pharmacol; 1997 Apr; 323(2-3):205-13. PubMed ID: 9128840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antihaemophilic effect of vasopressin, deamino-(D-arginine8)-vasopressin and adrenaline in sheep: proposal for an in vivo assay system.
    Heiniger J; Kissling-Albrecht L; Neuenschwander S; Rösli R; Pliska V
    Br J Pharmacol; 1988 Jun; 94(2):279-81. PubMed ID: 3134968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vasopressin antagonist inhibition of clotting factor release in the rhesus monkey (Macaca mulatta).
    Kinter LB; McConnell I; Goodwin BT; Campbell S; Huffman WF; Arthus MF; Lonergan M; Bichet DG
    J Pharmacol Exp Ther; 1992 May; 261(2):462-9. PubMed ID: 1578361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Subcutaneous injection of desmopressin (DDAVP) for increasing factor VIII and von Willebrand factor in plasmapheresis].
    Köhler M; Kotitschke R; Braun B; Hellstern P; Mörsdorf S; Pindur G; Heiden M; Wenzel E
    Beitr Infusionsther; 1990; 26():136-41. PubMed ID: 1703813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma concentrations of factor VIII after administration of DDAVP to conscious dogs.
    Vilhardt H; Barth T; Falch J; Nilsson IM
    Thromb Res; 1987 Sep; 47(5):585-91. PubMed ID: 3118500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid phase synthesis and some hormonal activities of 1-deamino-4-L-valine-8-D-homolysine-and 1-deamino-4-L-valine-8-D-homoarginine-vasopressin.
    Lindeberg G; Karlsson SM; Melin P
    Int J Pept Protein Res; 1977; 10(3):240-4. PubMed ID: 914427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII and tissue plasminogen activator in monkeys after administration of DDAVP analogues.
    Vilhardt H; Barth T
    Thromb Res; 1992 Dec; 68(6):501-4. PubMed ID: 1341062
    [No Abstract]   [Full Text] [Related]  

  • 18. Combined haemophilia A and type I von Willebrand's disease: a family study including an evaluation of the effects of DDAVP infusion.
    Casonato A; Pontara E; Boscaro M; Dannhauser D; Sartori MT; Girolami A
    Haematologia (Budap); 1993; 25(1):57-67. PubMed ID: 8339998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on the prolonged bleeding time in von Willebrand's disease.
    Mannucci PM; Pareti FI; Holmberg L; Nilsson IM; Ruggeri ZM
    J Lab Clin Med; 1976 Oct; 88(4):662-71. PubMed ID: 787458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological activities of some new arginine vasopressin analogues containing unusual amino acids.
    Varga C; Somlai C; Baláspiri L; László FA
    Acta Physiol Hung; 1993; 81(2):183-92. PubMed ID: 8197874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.